Aspartame: Scientific evaluation in the postmarketing period

被引:44
作者
Butchko, HH [1 ]
Stargel, WW
机构
[1] Nutrasweet Co, Med & Sci Affairs, Mt Prospect, IL 60056 USA
[2] Nutrasweet Co, Res & Dev, Mt Prospect, IL 60056 USA
关键词
aspartame; postmarketing surveillance; intake; acceptable daily intake; ADI; anecdotal reports; safety; review;
D O I
10.1006/rtph.2001.1500
中图分类号
DF [法律]; D9 [法律]; R [医药、卫生];
学科分类号
0301 [法学]; 10 [医学];
摘要
Prior to marketing, the safety of the high-intensity sweetener aspartame for its intended uses as a sweetener and flavor enhancer was demonstrated by the results of over 100 scientific studies in animals and humans. In the postmarketing period, the safety of aspartame was further evaluated through extensive monitoring of intake, postmarketing surveillance of anecdotal reports of alleged health effects, and additional research to evaluate these anecdotal reports and other scientific issues. The results of the extensive intake evaluation in the United States, which was done over an 8-year period, and the results of studies done in other countries demonstrated intakes which were well below the acceptable daily intakes set by the FDA and regulatory bodies in other countries, as well as the Joint FAO/WHO Expert Committee on Food Additives. Evaluation of the anecdotal reports of adverse health effects, the first such system for a food additive, revealed that the reported effects were generally mild and also common in the general population and that there was no consistent or unique pattern of symptoms that could be causally linked to consumption of aspartame. Finally, the results of the extensive scientific research done to evaluate these allegations did not show a causal relationship between aspartame and adverse effects. Thus, the weight of scientific evidence confirms that, even in amounts many times what people typically consume, aspartame is safe for its intended uses as a sweetener and flavor enhancer. (C) 2001 Elsevier Science.
引用
收藏
页码:221 / 233
页数:13
相关论文
共 166 条
[1]
ABRAMS IJ, 1992, ACS SYM SER, V484, P201
[2]
ABRAMS IJ, 1986, INT ASP WORKSH P NOV
[3]
*AG SAUD, 1999, FOR SCI DISC ASP
[4]
*AM MED ASS COUNC, 1985, JAMA-J AM MED ASSOC, V254, P400
[5]
AMERY WK, 1988, HEADACHE, V28, P624
[6]
[Anonymous], 1984, Aspartame: physiology and biochemistry
[7]
*ANZFA, 1997, 8 ANZFA
[8]
ASPINALL RL, 1980, J ENVIRON PATHOL TOX, V3, P387
[9]
BAR A, 1992, Z ERNAHRUNGSWISS, V31, P25, DOI 10.1007/BF01612550
[10]
BERGSTEN C, 1993, 3 SNT NORW FOOD CONT